Rapid WGS & WES in Childrens Hospitals - Fabric Genomics

She’s got a fighting chance, but she needs all the help she can get

Fabric Genomics’ high-speed interpretation platform provides more actionable results from whole genome and exome analysis

Whole Genome and Exome Testing in Children’s Hospitals

Up to 15% of infants in the United States require neonatal intensive care services, and up to 1/3 of these cases are diagnosed with underlying genetic conditions. Whole genome or exome sequencing can provide accurate and reliable results in children’s hospitals, leading to early intervention and superior pediatric outcomes. Fabric Genomics enables rapid and precise results, which is extremely critical for infants, especially those in the NICU and PICU.

See how Fabric Genomics enables rapid interpretation of whole genome sequencing at Rady Children’s Hospital.

Fabric Enterprise: The Precision Medicine Platform For Children’s Hospitals

Higher diagnostic yield icon via Fabric Genomics


Speed icon, fast genomic analysis


NGS analysis scalability


Icon - usability


Industry-leading Variant Interpretation

Robust data interpretation is critical to accurately identify genomic variants and deliver maximum diagnostic yield. Typical genome interpretation methods focus on filtering to identify and prioritize variants. Fabric Enterprise is an artificial intelligence (AI)-driven platform that combines deep phenotype and genotype data, enabling labs to achieve diagnostic yields ~2X compared to the industry standard (~50% vs. 25-30%, respectively). Plus, Fabric Enterprise is always up to date with the latest reference data and standard guidelines to enable accurate variant interpretation and classification.

Fabric Enterprise enables increased yield of clinically relevant candidates. Histogram of cases returned with causal candidate genes/variants (%). 50% of cases returned with a causal candidate gene/variants in Genomics England case study; 58% of cases returned with a causal candidate gene/variants in LabCorp Integrated Genetics case study; 30% of cases returned with a causal candidate gene/variants as the current industry standard.

To learn more about this data, download the posters.

Rapid Diagnostic Solutions for Life-changing Interventions

A limiting factor for exome or whole genome sequencing is the time between sample collection and results reported. This turnaround time (TAT) is influenced by multiple factors, including diagnostic methodology and on-site resources.

Fabric Enterprise is an all-in-one platform for secondary analysis, interpretation, and reporting. Fabric Enterprise employs proven AI-driven prioritization to deliver a rapid TAT from VCF data to clinical results.

Fast, AI-driven analysis greatly reduces the amount of time needed to analyze each case, allowing your staff to focus on the most likely causative candidates first — and report more cases in less time.


Powerful Genomic Interpretation for Children’s Hospitals of All Sizes

Fabric Enterprise is designed to support all NGS-based diagnostic tests regardless of test type or scale. Starting from either raw data or variant calls from whole genome, exome, or panel tests, Fabric Enterprise provides efficient workflows for genome annotation, interpretation, clinical report generation, and sign-off. And Fabric’s scalable cloud solution incorporates comprehensive data and network security protocols.

Powerful Functionality Meets Intuitive Design

Fabric Enterprise is built for ease of use so you can focus on getting results rather than getting help

Icon - lightbulb

Intuitive, easy to learn interface

Checklist icon referring to steps of an ngs workflow on Fabric Genomics

Robust & comprehensive onboarding

Icon - support

Exceptional support

See how Fabric Genomics enables rapid interpretation of whole genome sequence data at Rady Children’s Hospital.

Watch the Webinar

Kataryzna Ellsworth, PhD FACMG discusses implementation and scaling of rapid genome testing at Rady Children’s Hospital

Clinical implementation of rapid genome testing

Fabric Enterprise can enable next-generation breakthroughs for your youngest patients